Abstract:Human telomeres are composed of long repeating sequences of TTAGGG, associated with a variety of telomere‐binding proteins. Its function as an end‐protector of chromosomes prevents the chromosome from end‐to‐end fusion, recombination and degradation. Telomerase acts as reverse transcriptase in the elongation of telomeres, which prevent the loss of telomeres due to the end replication problems. However, telomerase activity is detected at low level in somatic cells and high level in embryonic stem cells and tumo… Show more
“…Hybridization with a telomere-specific probe (e.g., radioactively labeled) is performed and telomere length is usually assessed by densitometric analysis of the highest peak TRF signal after exposure of the blot to light-sensitive film or to a phosphorimager. 39,40 However, this well-established methodology harbors several inherent disadvantages. For example, Southern blots require relatively large amounts (i.e.…”
Section: Methods Of Telomere Measurementmentioning
confidence: 99%
“…Several methods have been developed to measure telomere length, or its proxies, and have been recently reviewed by Lin and Yan 39 and by Baird. 40 These include the well-established Southern blot method, the telomere DNA content (TC) titration assay 41,42 and telomere fluorescence in situ hybridization (FISH).…”
Section: Methods Of Telomere Measurementmentioning
confidence: 99%
“…In addition, Southern blot radiographs often display multiple peaks, leading to a high variability in interpretation. 39,40 A method for assessing the total content of telomere DNA sequences (TC), a surrogate for telomere length, in genomic DNA was recently reported. 41,42 Briefly, genomic DNA is immobilized on membranes in a slot blot format and titrated by hybridization with a telomere-specific probe, either normalized to centromeric DNA 41 or to total genomic DNA in the same sample.…”
Section: Methods Of Telomere Measurementmentioning
Solid tumors continue to affect millions of people worldwide. Increasingly sophisticated diagnostic tools contribute to the high incidence rates for some tumor types, and treatment options continue to expand. However, the progression of solid tumors represents a challenge for the appropriate treatment of individual patients because of the relative inaccuracy of current prognostic markers, including the widely used Tumor-Nodes-Metastasis (TNM) staging system, to predict the course of disease. As a result, both over-and undertreatment are clinical realities in the management of patients diagnosed with solid tumors. Therefore, populationbased screening programs that increase the overall cancer incidence rates are controversial, as they may do little to improve the patient's quality of life. Consequently, there is a strong need to develop novel and independent markers of prognosis. In this context, we review the use of telomeres as prognostic markers for solid tumors, including cancers from lung, breast, prostate, colon, brain and head and neck. Telomeric sequences, the repetitive DNA at the end of human chromosomes, are mediators of genomic stability and can undergo length alterations during tumor initiation and progression. In a number of studies reviewed here, these alterations, measured as telomere attrition and elongation, have been shown either to be associated with clinical markers of disease progression or to be independent markers of cancer prognosis. We conclude from these studies that careful assessment of telomere length or its proxies, such as telomere DNA content, will be part of novel risk assessment and prognostic modalities for patients with solid tumors. ' 2006 Wiley-Liss, Inc.
“…Hybridization with a telomere-specific probe (e.g., radioactively labeled) is performed and telomere length is usually assessed by densitometric analysis of the highest peak TRF signal after exposure of the blot to light-sensitive film or to a phosphorimager. 39,40 However, this well-established methodology harbors several inherent disadvantages. For example, Southern blots require relatively large amounts (i.e.…”
Section: Methods Of Telomere Measurementmentioning
confidence: 99%
“…Several methods have been developed to measure telomere length, or its proxies, and have been recently reviewed by Lin and Yan 39 and by Baird. 40 These include the well-established Southern blot method, the telomere DNA content (TC) titration assay 41,42 and telomere fluorescence in situ hybridization (FISH).…”
Section: Methods Of Telomere Measurementmentioning
confidence: 99%
“…In addition, Southern blot radiographs often display multiple peaks, leading to a high variability in interpretation. 39,40 A method for assessing the total content of telomere DNA sequences (TC), a surrogate for telomere length, in genomic DNA was recently reported. 41,42 Briefly, genomic DNA is immobilized on membranes in a slot blot format and titrated by hybridization with a telomere-specific probe, either normalized to centromeric DNA 41 or to total genomic DNA in the same sample.…”
Section: Methods Of Telomere Measurementmentioning
Solid tumors continue to affect millions of people worldwide. Increasingly sophisticated diagnostic tools contribute to the high incidence rates for some tumor types, and treatment options continue to expand. However, the progression of solid tumors represents a challenge for the appropriate treatment of individual patients because of the relative inaccuracy of current prognostic markers, including the widely used Tumor-Nodes-Metastasis (TNM) staging system, to predict the course of disease. As a result, both over-and undertreatment are clinical realities in the management of patients diagnosed with solid tumors. Therefore, populationbased screening programs that increase the overall cancer incidence rates are controversial, as they may do little to improve the patient's quality of life. Consequently, there is a strong need to develop novel and independent markers of prognosis. In this context, we review the use of telomeres as prognostic markers for solid tumors, including cancers from lung, breast, prostate, colon, brain and head and neck. Telomeric sequences, the repetitive DNA at the end of human chromosomes, are mediators of genomic stability and can undergo length alterations during tumor initiation and progression. In a number of studies reviewed here, these alterations, measured as telomere attrition and elongation, have been shown either to be associated with clinical markers of disease progression or to be independent markers of cancer prognosis. We conclude from these studies that careful assessment of telomere length or its proxies, such as telomere DNA content, will be part of novel risk assessment and prognostic modalities for patients with solid tumors. ' 2006 Wiley-Liss, Inc.
“…23,24 In this study, we explored the feasibility of using paraffin-embedded tissues for the quantitative assessment of telomere length together with highthroughput methylation quantification on MALDI-TOF silico-chips. 20,21 Before carrying out telomere length analysis, yield of extracted DNA from formalin-fixed paraffin-embedded tissues was quantified using NanoDrop ND-1000 spectrophotometer (Biolab, Mulgrave, Vic, Australia).…”
Section: Telomere Length Quantification and Methylation Analysis Usinmentioning
Unregulated cell growth, a major hallmark of cancer, is coupled with telomere shortening. Measurement of telomere length could provide important information on cell replication and proliferation state in cancer tissues. Telomere shortening and its potential correlation with downregulation of cell-cycle regulatory elements were studied by the examination of relative telomere length and methylation status of the TP53, P21 and P16 promoters in tissues from breast cancer patients. Telomere length was measured in 104 samples (52 tumors and paired adjacent normal breast tissues) by quantitative PCR. Methylation profile of selected genes was analyzed in all samples using a matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Our results demonstrated a significant shortening of tumor telomere regions compared with paired adjacent normal tissues (Po0.001). Similarly, telomere lengths were significantly shorter in advanced stage cases and in those with higher histological grades (Po0.05). Telomere shortening in cancer tissues was correlated with a different level of hypermethylation in the TP53, P21 and P16 promoters (r ¼ À0.33, P ¼ 0.001; r ¼ À0.70, Po0.0001 and r ¼ À0.71, Po0.0001, respectively). The results suggested that inactivation of p16/Rb and/or p53/p21 pathways by hypermethylation may be linked to critical telomere shortening, leading to genome instability and ultimately to malignant transformation. Thus, telomere shortening and promoter hypermethylation of related genes both might serve as breast cancer biomarkers.
“…Numerous methods are available to determine telomere length in blood and other cell types, and have been reviewed elsewhere (Baird 2005;Lin and Yan 2005). Telomere length in genomic DNA is often determined by terminal restriction fragment (TRF) measurement on Southern blots, or by quantitative polymerase chain reaction (QPCR).…”
Telomeres, consisting of nucleotide repeats and a protein complex at chromosome ends, are essential in maintaining chromosomal integrity. Dyskeratosis congenita (DC) is the inherited bone marrow failure syndrome (IBMFS) that epitomizes the effects of abnormal telomere biology. Patients with DC have extremely short telomere lengths (<1 st percentile) and many have mutations in telomere biology genes. Interpretation of telomere length in other IBMFSs is less straightforward. Abnormal telomere shortening has been reported in patients with apparently acquired hematologic disorders, including aplastic anemia, myeolodysplasia, paroxysmal nocturnal hemoglobinuria, and leukemia. In these disorders, the shortest lived cells have the shortest telomeres, suggestive of increased hematopoietic stress. Telomeres are also markers of replicative and/or oxidative stress in other complex disease pathways, such as inflammation, stress, and carcinogenesis.The spectrum of related disorders caused by mutations in telomere biology genes extends beyond classical DC to include marrow failure that does not respond to immunosuppression, idiopathic pulmonary fibrosis, and possibly other syndromes. We suggest that such patients are categorized as having an inherited disorder of telomere biology. Longitudinal studies of patients with very short telomeres but without classical DC are necessary to further understand the long-term sequelae, such as malignancy, osteonecrosis/osteoporosis, and pulmonary and liver disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.